Votrient is owned by Novartis.
Votrient contains Pazopanib Hydrochloride.
Votrient has a total of 1 drug patent out of which 0 drug patents have expired.
Votrient was authorised for market use on 19 October, 2009.
Votrient is available in tablet;oral dosage forms.
The generics of Votrient are possible to be released after 19 October, 2023.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7105530||NOVARTIS||Pyrimidineamines as angiogenesis modulators|| |
(8 months from now)
Market Authorisation Date: 19 October, 2009
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic